Shahram Hejazi, PhD
Co-Founder, Chief Executive Officer, and Board Director
Dr. Shahram Hejazi is a life science investor/entrepreneur with executive general management experience in early-stage ventures and large global companies. Over his 20+ year career, Shahram has founded and/or directed the growth of more than a dozen startup companies. He is a Venture Partner with BioAdvance (a venture capital firm), where he leads the investments in a number of key life science sectors. He also serves on the Board of several companies. Dr. Hejazi was the 2014 James Wei Visiting Professor of Entrepreneurship at Princeton University where he is currently teaching a couple courses on entrepreneurship.
Prior to these, Dr. Hejazi was the President of Kodak's life science division, where he had global responsibility for R&D, manufacturing, operations, sales, marketing and service. Before Kodak, he was the CEO of Zargis Medical Corp. (a Siemens spinoff) where he led the company from raising capital and the technology development to completion of several clinical trials, successful FDA regulatory approval and product launch. Prior to Zargis, he was the Head of the Strategic Business Development at Siemens medical.
Dr. Hejazi has a PhD in electrical engineering with emphasis in biophysics from State University of New York at Buffalo, and an executive business education from Stanford University.
Robert K Prud'homme, PhD
Co-founder, Chief Scientific Advisor, and Board Director
Dr. Prud'homme is a Professor of Chemical and Biological Engineering and was the Inaugural Director of the Program in Engineering Biology at Princeton University. Dr. Prud'homme led an NSF NIRT multi-university program on nanoparticle formation leading to the discovery of Flash NanoPrecipitation technology.
Dr. Prud'homme has served on the executive committees of the American Institute of Chemical Engineers Materials Science Division and the U.S. Society of Rheology. He was Chair of the Technical Advisory Board for Material Science Research for Dow Chemical Company and was on BASF's nanotechnology advisory committee. He is a winner of the Presidential Young Investigator award from the NSF. Dr. Prud'homme has authored over 200 publications and filed over 25 patents.
Jason Smith, PhD
Dr. Smith led the first institutional investment in Optimeos in 2016. He joined IP Group in 2014 with extensive experience developing and commercialising healthcare technology in a variety of settings. Prior to this, he served as Director of Clinical Affairs, Director of Marketing and Product Manager at photonic therapy startup, LiteCure. Dr. Smith spent 4 years with W.L. Gore as a Product Specialist in the Medical Division where he developed and managed products for bariatric and colorectal surgery and biliary stenting. He has a PhD in Biomedical Engineering from Duke University and an MS and BS in Materials Science and Engineering from North Carolina State University.
Marie Lindner, MD
Dr. Lindner has a distinguished career as a medical doctor, in global biopharmaceutical companies, and in entrepreneurial life sciences companies. She is currently the Global Program Head within the Strategic Partnership Team at Novartis. Before this, she was the Senior Director of Scientific Licensing and Business Development at Shire Pharmaceuticals. Prior to Shire, Dr. Lindner was a Venture Partner at BioAdvance, where she worked closely with therapeutic-focused portfolio companies and provided management teams with strategic advice, business, and regulatory/clinical strategy counsel.
Before BioAdvance, Dr. Lindner served as SVP, Medical & Business Affairs at Isolagen; VP, Strategic Business Development at BTG International; and VP, Medical Market Strategy, Elan Drug Delivery. In addition, she worked in various business and clinical roles at SmithKline Beecham (now GSK) and Rhône-Poulenc Rorer (now sanofi-aventis) supporting small molecule and biologic therapies.
Dr. Lindner became board certified in internal medicine and clinical nutrition, completed a general surgery residency and a fellowship in atherosclerosis prior to nearly two decades of business experience.